For years, customers have been demanding more from their financial institutions. Covid-19, and the consequences that came from the pandemic only accelerated these customer demands. Consumers expect immediacy, personalized, and flawless interactions with their favorite brands and they expect the same from their banks.
Bitcoin investor conviction appears to be at all-time-highs, alongside numerous metrics ranging from price, to hash-rate, to proportion of mature coin supply.
Bioventus recently announced that its shareholders approved its agreement to acquire Misonix. Bioventus agrees to pay Misonix shareholders either 1.6839 shares of Bioventus class A common stock or $28.00 for each share of Misonix common stock held. The amount paid to Misonix shareholders results in an approximate valuation of $518 million for Misonix, based on share prices from around the time the acquisition agreement was reached. With the completion of this acquisition, Misonix will become a wholly-owned subsidiary of Bioventus.
Misonix develops minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products for a variety of orthopedic applications. For example, Misonix is the developer of the BoneScalpel, an ultrasonic bone cutting tool. Additionally, Misonix is the developer of the Nexus, an ultrasonic surgical aspirator for precision hard and soft tissue removal.
In a press release, Bioventus’ CEO Ken Reali stated:
We are pleased by the outcome of today’s vote and thank our stockholders for supporting the acquisition. The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients. We are excited to welcome the Misonix team to Bioventus.
Bioventus plans to accelerate the adoption of Misonix’s BoneScalpel and Nexus products through the footprint of Bioventus in the spine surgical solutions area. Bioventus also plans to augment its current lower extremity product offerings with Misonix’s products.
This acquisition is one of three acquisitions by Bioventus this year. Earlier this year, Bioventus acquired Bioness, the developer of neuromodulation and rehabilitation medical devices. Bioventus also has an agreement in place to acquire CertiHeal, the developer of the Agili-C implant.
“Those who tell the stories rule society.” Plato Coca-Cola is making noise with its first global campaign since 2016. During its rollout, Selman Careaga, president of the global Coca-Cola category, called the Real Magic campaign, “a new philosophy that will guide everything we do with our brand,” adding that Coca-Cola, “will invite everyone to embrace the magic of humanity.” Coca-Cola celebrated the ‘Real Magic’ […]
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President: Yasuhiko Saitoh) is announcing that it is ready to supply a unique set of transfer parts...
We will supply the essential parts and equipment needed to transfer Micro LED chips from LED wafer to backplane to help reach the goal of mass production of Micro LED displays Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President: Yasuhiko Saitoh) is announcing that it is ready to supply a unique set of transfer parts […]
I hated the the FDA eSubmitter template which was discontinued May 30, 2021. Finally we have eSTAR draft guidance for the new eSTAR template. History of 510k electronic submissions The FDA has experimented with a multitude of pilot 510k submission programs over the years to streamline and improve the 510k submission content, formatting, and to […]
Anthony Arundel, co-author of Harnessing public research for innovation in the 21st Century: An international assessment of knowledge transfer policies, discusses the main gaps in our understanding of how knowledge transfer works and key considerations for policymakers in crafting effective knowledge transfer policies for the future.
Graphenel JSC, based in Ho Chi Minh City, is a technology company with a novel approach to graphene production. Jane Phung, the company’s international business development manager, discusses the role IP plays in supporting Graphenel’s ambition to become a leading supplier of graphene-based materials.
